Consequently, we posit that the TRKA‐GRB2‐EVI1‐CRLS1 signaling pathway could function as a screening metric to identify prospective pharmaceuticals targeting CL for PD prevention (Figure 9). Here, MECOM is linked to Parkinson disease.